Basal Cytokeratins in Breast Tumours and BRCA Mutations
Author Information
Author(s): Eerola Hannaleena, Heinonen Mira, Heikkilä Päivi, Kilpivaara Outi, Tamminen Anitta, Aittomäki Kristiina, Blomqvist Carl, Ristimäki Ari, Nevanlinna Heli
Primary Institution: Helsinki University Central Hospital
Hypothesis
Can basal cytokeratins help identify BRCA1 and BRCA2 mutation carriers in breast cancer patients?
Conclusion
Basal cytokeratins can assist in identifying BRCA1 mutation carriers, but their predictive power is weaker than previously thought.
Supporting Evidence
- CK-14 was significantly associated with BRCA1 mutation status.
- CK-5/6 expression was linked to high-grade tumours.
- Tumours expressing basal CKs were more likely to be ER negative and PR negative.
- The most effective predictors of BRCA1 mutations were age at onset, HER2 status, and ER or PR status.
Takeaway
This study looked at certain markers in breast cancer to see if they could help find people with BRCA1 or BRCA2 gene changes. They found that while these markers can help, they aren't as strong at predicting these changes as they thought.
Methodology
The study used breast cancer tumour microarrays to evaluate the expression of cytokeratins in various breast cancer patient groups.
Potential Biases
Potential biases may arise from the selection of patients and the methods used for immunohistochemical analysis.
Limitations
The study's findings may not be directly comparable to other studies due to differences in methodologies and cut-off points for positivity.
Participant Demographics
Participants included breast cancer patients from BRCA1, BRCA2, non-BRCA1/BRCA2 families, and sporadic cases.
Statistical Information
P-Value
p<0.0005
Confidence Interval
95% CI = 4.3 to 29.2
Statistical Significance
p<0.0005
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website